

Substitute Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
07917-178001Application No.
10/719,054**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

(37 CFR 1.98(b))

Applicant
Jones et al.Filing Date
November 20, 2003Group Art Unit
1632**U.S. Patent Documents**

| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate |
|------------------|-----------|-----------------|------------------|-------------------------|-------|----------|----------------------------|
| UKS | AA | 4,215,051 | Jul. 29, 1980 | Schroeder, et al. | | | |
| | AB | 4,522,811 | June 11, 1985 | Eppstein, et al. | | | |
| | AC | 4,683,202 | Jul. 28, 1987 | Mullis | | | |
| | AD | 4,868,103 | Sept. 19, 1989 | Stavrianopoulos, et al. | | | |
| | AE | 5,223,409 | June 29, 1993 | Ladner, et al. | | | |
| | AF | 5,272,071 | Dec. 21, 1993 | Chappel | | | |
| | AG | 5,283,317 | Feb. 1, 1994 | Saifer, et al. | | | |
| | AH | 5,328,470 | Jul. 12, 1994 | Nabel, et al. | | | |
| | AI | 5,459,039 | Oct. 17, 1995 | Modrich, et al. | | | |
| | AJ | 5,498,531 | Mar. 12, 1996 | Jarrell | | | |
| | AK | 5,631,169 | May 20, 1997 | Lakowicz, et al. | | | |
| | AL | 5,695,937 | Dec. 9, 1997 | Kinzler, et al. | | | |
| | AM | 5,851,984 | Dec. 22, 1998 | Matthews et al. | | | |
| | AN | 5,854,033 | Dec. 29, 1998 | Lizardi | | | |
| | AO | 5,876,742 | Mar. 2, 1999 | Cochrum, et al. | | | |
| | AP | 6,159,462 | Dec. 12, 2000 | Matthews et al. | | | |
| ✓ | AQ | 20020049177 | Apr. 25, 2002 | Clark et al. | | | |

Foreign Patent Documents or Published Foreign Patent Applications

| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation | |
|------------------|-----------|-----------------|------------------|--------------------------|-------|----------|-------------|----|
| | | | | | | | Yes | No |
| UKS | AR | WO 94/10300 | 05/11/04 | WIPO | | | | |
| UKS | AS | WO 91/06667 | 05/16/91 | WIPO | | | | |
| | AT | | | | | | | |
| | AU | | | | | | | |
| | AV | | | | | | | |
| | AW | | | | | | | |

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|---------------------------------------|-------------------------------|
| Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 07917-178001 | Application No. 10/719,054 |
| | Applicant Jones et al. | | |
| | Filing Date November 20, 2003 | Group Art Unit 1632 | |

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|-------------------------------------------------------------------------|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Examiner Initial | Desig. ID | Document |
| MB | AX | Austin et al., "A role for the Wnt gene family in hematopoiesis: expansion of multilineage progenitor cells," Blood 89(10):3624-635 (1997) |
| | AY | Bai et al., Effective transduction and stable transgene expression in human blood cells by a third-generation lentiviral vector," Gene Ther. 10(17):1446-57 (2003) |
| | AZ | Cavazzana-Calvo et al., "Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease," Science 288(5466):669-72 (2000) |
| | AAA | Fry and Mackall, "Interleukin-7: from bench to clinic," Blood 99(11):3892-904 (2002) |
| | ABB | He et al., "A member of the frizzled protein family mediating axis induction by Wnt-5a," Science 275:652-654 (1997) |
| | ACC | Holmen et al., "A novel set of Wnt-Frizzled fusion proteins identifies receptor components that activate beta-catenin-dependent signaling," J. Biol. Chem. 277(38):34727-35 (2002) |
| | ADD | Iozzo et al., "Aberrant expression of the growth factor Wnt-5A in human malignancy," Cancer Res. 55(16):3495-499 (1995) |
| | AEE | Jönsson et al., "Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas," Cancer Res. 62(2):409-16 (2002) |
| | AFF | Jordan et al., "Long-term repopulating abilities of enriched fetal liver stem cells measured by competitive repopulation," Exp. Hematol. 23:1011-1015 (1995) |
| | AGG | Jurecic et al., "Enrichment and functional characterization of Sca-1 ⁺ WGA ⁺ , Lin-WGA ⁺ , Lin-Sca-1 ⁺ , and Lin-Sca-1 ⁺ WGA ⁺ bone marrow cells from mice with an Ly-6a haplotype," Blood 82(9):2673-83 (1993) |
| | AHH | Kawakami et al., "WNT signals control FGF-dependent limb initiation and AER induction in the chick embryo," Cell 104(6):891-900 (2001) |
| | AII | Kühl et al., "Ca ²⁺ /calmodulin-dependent protein kinase II is stimulated by Wnt and Frizzled homologs and promotes ventral cell fates in Xenopus," J. Biol. Chem. 275(17):12701-11 (2000) |
| | AJJ | Kühl et al., "Antagonistic regulation of convergent extension movements in Xenopus by Wnt/beta-catenin and Wnt/Ca ²⁺ signaling," Mech Dev. 106(1-2):61-76 (2001) |
| | AKK | Lejeune et al., "Wnt5a cloning, expression, and up-regulation in human primary breast cancers," Clin. Cancer Res 1(2):215-22 (1995) |
| | ALL | Li and Johnson, "Murine hematopoietic stem and progenitor cells: I. Enrichment and biologic characterization," Blood 85(6):1472-9 (1995) |
| | AMM | Liang et al., "Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue," Cancer Cell 4(5):349-60 (2003) |
| | ANN | Liang et al., "A role for Wnt5a in B cell growth and tumorigenesis," Proc. Amer. Assoc. Cancer Research, Annual Meeting 43:667, Abstract #3310 (2002) |
| | AOO | Olson et al., "Reversion of uroepithelial cell tumorigenesis by the ectopic expression of human wnt-5a," Cell Growth Differ. 8(4):417-23 (1997) |
| | APP | Phillips et al., "The genetic program of hematopoietic stem cells," Science 288(5471):1635-40 (2000) |
| | AQQ | Rimerman et al., "Wnt1 and MEK1 cooperate to promote cyclin D1 accumulation and cellular transformation," J. Biol. Chem. 275(19):14736-42 (2000) |
| ✓ | ARR | Schmidt-Wolf and Schmidt-Wolf, "Gene therapy for hematological malignancies," Clin. Exp. Med. 3(1):4-14 (2003) |

| | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| Examiner Signature <i>MB Jones</i> 1/31/06 | Date Considered |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | |
|--------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|---------------------------------------|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 07917-178001 | Application No. 10/719,054 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant Jones et al. | |
| | | Filing Date November 20, 2003 | Group Art Unit 1632 |

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|-------------------------------------------------------------------------|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Examiner Initial | Desig. ID | Document |
| AKS | ASS | Slusarski et al., "Modulation of embryonic intracellular Ca ²⁺ signaling by Wnt-5A," Dev. Biol. 182(1):114-20 (1997) |
| | ATT | Toyofuku et al., "Wnt/frizzled-2 signaling induces aggregation and adhesion among cardiac myocytes by increased cadherin-beta-catenin complex," J. Cell. Biol. 150(1):225-41 (2000) |
| | AUU | Van Den Berg et al., "Role of members of the Wnt gene family in human hematopoiesis," Blood 92(9):3189-202 (1998) |
| | AVV | Weeraratna et al., "Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma," Cancer Cell. 1 (3):279-88 (2002) |
| | AWW | Whitlock et al., "Murine B cell lymphopoiesis in long term culture," J. Immunol. Methods 67(2):353-69 (1984) |
| | AXX | Willert et al., "A transcriptional response to Wnt protein in human embryonic carcinoma cells," BMC Dev. Biol. 2(1):8. Epub 2002 Jul 02 (2002) |
| | AYY | Yamaguchi et al., "A Wnt5a pathway underlies outgrowth of multiple structures in the vertebrate embryo," Development 126(6):1211-23 (1999) |
| ✓ | AZZ | |

| | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| Examiner Signature <i>AKS</i> 1/31/06 | Date Considered |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |